A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach
Crossref DOI link: https://doi.org/10.1007/s40487-019-0097-7
Published Online: 2019-07-19
Published Print: 2020-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wang, Xiaomin
Chen, Jian
Reyes, Josephine
Zhou, Simon
Palmisano, Maria
Li, Yan http://orcid.org/0000-0001-7609-2683
Funding for this research was provided by:
Celgene Corporation
Article History
Received: 14 June 2019
First Online: 19 July 2019